Explore

Trendline Trendline
Kivu Bioscience Names Mohit Trikha as CEO to Drive Oncology Innovations

Kivu Bioscience Names Mohit Trikha as CEO to Drive Oncology Innovations

Kivu Bioscience Names Mohit Trikha as CEO to Drive Oncology Innovations
Trendline Trendline
Kivu Bioscience to Showcase ADC Innovations at AACR Annual Meeting 2026

Kivu Bioscience to Showcase ADC Innovations at AACR Annual Meeting 2026

Kivu Bioscience to Showcase ADC Innovations at AACR Annual Meeting 2026
Trendline Trendline
Kivu Bioscience to Present Preclinical Data on Next-Generation ADC Programs at AACR Annual Meeting

Kivu Bioscience to Present Preclinical Data on Next-Generation ADC Programs at AACR Annual Meeting

Kivu Bioscience to Present Preclinical Data on Next-Generation ADC Programs at AACR Annual Meeting
Trendline Trendline
Parabilis Medicines Expands Leadership Team to Drive Cancer Drug Development

Parabilis Medicines Expands Leadership Team to Drive Cancer Drug Development

Parabilis Medicines Expands Leadership Team to Drive Cancer Drug Development
Trendline Trendline
Eli Lilly Acquires CrossBridge Bio to Enhance Antibody-Drug Conjugate Development

Eli Lilly Acquires CrossBridge Bio to Enhance Antibody-Drug Conjugate Development

Eli Lilly Acquires CrossBridge Bio to Enhance Antibody-Drug Conjugate Development
Trendline Trendline
San Diego Startup Neomorph Secures $100M for Cancer Drug Development

San Diego Startup Neomorph Secures $100M for Cancer Drug Development

San Diego Startup Neomorph Secures $100M for Cancer Drug Development
Trendline Trendline
San Diego Startup Neomorph Secures $100 Million Investment for Cancer Drug Development

San Diego Startup Neomorph Secures $100 Million Investment for Cancer Drug Development

San Diego Startup Neomorph Secures $100 Million Investment for Cancer Drug Development
Trendline Trendline
Eli Lilly Acquires CrossBridge Bio, Enhancing Cancer Treatment Capabilities

Eli Lilly Acquires CrossBridge Bio, Enhancing Cancer Treatment Capabilities

Eli Lilly Acquires CrossBridge Bio, Enhancing Cancer Treatment Capabilities
Trendline Trendline
Iterion Therapeutics Presents New Data on Tegavivint for Wnt-Driven Cancers at AACR Meeting

Iterion Therapeutics Presents New Data on Tegavivint for Wnt-Driven Cancers at AACR Meeting

Iterion Therapeutics Presents New Data on Tegavivint for Wnt-Driven Cancers at AACR Meeting
Trendline Trendline
Adcendo Secures $75 Million to Advance Antibody-Drug Conjugate Pipeline for Cancer Treatment

Adcendo Secures $75 Million to Advance Antibody-Drug Conjugate Pipeline for Cancer Treatment

Adcendo Secures $75 Million to Advance Antibody-Drug Conjugate Pipeline for Cancer Treatment
Trendline Trendline
Eli Lilly to Acquire CrossBridge Bio to Enhance Antibody-Drug Conjugate Development

Eli Lilly to Acquire CrossBridge Bio to Enhance Antibody-Drug Conjugate Development

Eli Lilly to Acquire CrossBridge Bio to Enhance Antibody-Drug Conjugate Development
Trendline Trendline
Revolution Medicines Achieves Breakthrough in Pancreatic Cancer Treatment with RASolute 302 Trial

Revolution Medicines Achieves Breakthrough in Pancreatic Cancer Treatment with RASolute 302 Trial

Revolution Medicines Achieves Breakthrough in Pancreatic Cancer Treatment with RASolute 302 Trial